Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Zakattack who wrote (14399)	5/5/1998 9:50:00 AM
From: TokyoMex	Read Replies (2) \| Respond to of 34592

Be careful,, folks liked IMGN ,, but whole sector got killed today . Today ISDN for a quick bite A momentum carried intermediate play ,, the normal rules,,, at your own risk ,, for 2 - 3 days play ,, Close 5/4/98 1 5/8 by 1 3/4 52 week low: 7/16 52 week high: 4 7/8 Shares Outst: 29M Float: 2.5M Effective float: 200-300K Website: kttp://www.globalnet1.net Website of their subsidiary, On Line Enterrtainment: oen.com GlobalNet Systems is a full-service, high-speed all-digital Internet Service Provider, which is also involved in developing a high-speed network for Voice Over IP reduced rate long-distance telephone service on a dedicated network. GlobalNet Systems has headquarters in Chatsworth, Calif., and can be reached via the Internet at www.globalnet1.net. Snippets from the SI Thread >>here is an overlooked internet play where the main business is a full-service, high-speed, all digital Internet Service Provider, which is also involved in developing a high-speed network for Voice Over IP reduced rate long distance telephone service on a dedicated network. See their website: globalnet1.net Their subsidiary, On-Line Entertainment Network (http://www.oen.com) has an agreement with Time Warner to sample as well as sell their products on line.<< >>I have info... I talked to the CEO of ISDN. GET THIS: 29 mill. out, 2.5 mill. float, he said in reality based on what he knows about the holders, the float is only about 200,000 shares, they are going to be SEC reporting, they are an ISP (internet service provider), they are discussing telephony, they may spin-off (on-line Entertainment Inc.) to shareholders, they are going into video-on-demand, they are loading the content now for the music on-line, they have big projections, 98 will be in millions and will be profitable by end of year, NEWS OUT IN THE NEXT DAY OR TWO, he said their music technology is better than KTEL's 212-307-1333 Do your DD. Just my opinion. Everyone is looking for that undiscovered internet stock. << >>President kept his word...Good News Friday! ...highlights their superior audio web capabilities...that technology is worth a lot!! (many more contracts coming) and their other business of helping businesses get high speed internet ISDN access in CA also strong....this one is clearly undervalued IMHO. Excellent areas to be in...will do more DD next week. Will report back.<< Press Releases Friday May 1, 7:01 am Eastern Time Company Press Release On-Line Entertainment Network Inc. Sets Exclusive Licensing Agreement With Spring Communications Inc. Deal Provides for Worldwide Audio Netcasts of Spring Communications' Pay-Per-View Events Via OEN's Internet-Based "SongQuest" System LOS ANGELES--(BUSINESS WIRE)--May 1, 1998-- ''Spring'' Concert Area to be Created on the ''SongQuest'' System On-Line Entertainment Network Inc. (OEN), a wholly owned subsidiary of GlobalNet Systems Ltd. (Nasdaq BB:ISDN - news), Friday announced an exclusive pay-per-listen licensing agreement with Spring Communications Inc. to provide worldwide audio netcasts of Spring pay-per-view concerts and other special events via OEN's Internet-based ''SongQuest'' audio-on-demand system (www.oen.com). Tuesday March 31, 7:02 am Eastern Time Company Press Release On-Line Entertainment Network, Inc. and its 'SongQuest' System to Offer Sound Samples and CD's from Warner Music Group Listeners Will Be Able To Access Samples of and Purchase Warner-Distributed CD's Released by Such Labels as Atlantic, Electra/Asylum, Reprise and Warner Bros. Records Warner Music Group Area to be Created on the 'SongQuest' System LOS ANGELES--(BUSINESS WIRE)--March 31, 1998--On-Line Entertainment Network, Inc. (OEN), a wholly-owned subsidiary of GlobalNet Systems, Ltd. (Nasdaq BB:ISDN - news), announced Tuesday a licensing agreement with Warner Music Group which will allow OEN's ''SongQuest'' audio-on-demand system users (www.oen.com) to access and listen to 30-second samples of Warner-distributed cd's released by such labels as Atlantic, electra/Asylum, Reprise and Warner Bros. Records. Tuesday February 17, 7:03 am Eastern Time Company Press Release Rhythm & Blues Foundation Ninth Annual Pioneer Awards Set for Live Worldwide Cybercast Via On-Line Entertainment Network's "SongQuest" System Pay-Per-Listen Event to Feature Smokey Robinson, Will Downing, Gladys Knight and The Pips and Bonnie Raitt, Among Many Others LOS ANGELES--(ENTERTAINMENT WIRE)--Feb. 17, 1998-- The Rhythm & Blues Foundation Ninth Annual Pioneer Awards will be cybercast live to a worldwide audience via On-Line Entertainment Network's (OEN) ''SongQuest'' system (www.oen.com). The pay-per-listen gala will be netcast live from the New York Sheraton on Thursday, Feb. 26, at 8 p.m. ET and feature such stars as Smokey Robinson, Will Downing, Branford Marsalis and Bonnie Raitt. In addition to the award presentations, listeners will experience rare, historical performances from the 1998 Pioneer honorees, including Herb Abramson, Faye Adams, Bobby Byrd, Tyrone Davis, Screamin' Jay Hawkins, The O'Jay's, Ernie K-Doe, Kim Weston, David ''Fathead'' Newman, The Five Satins and The Harptones. Gladys Knight and The Pips, recipients of the Lifetime Achievement Award, will also perform live.

To: Zakattack who wrote (14399)	5/5/1998 9:53:00 AM
From: KLAW97	Read Replies (2) \| Respond to of 34592

SPTA Cancer drug cure company small float 17,000 shares short just signed a deal with Schering-plough currently 15/32 x 1/2 <<< Dr. Jerry B. Hook, Sparta's chairman, president and CEO commented, ''We are pleased to be working with Schering-Plough in this effort to expand the TEMODAL product line. Spartaject Technology has proven to be an effective and potentially less toxic delivery system for water insoluble compounds. Our preliminary work with temozolomide has encouraged both companies to move forward with this project.'' >>> <<<<Wednesday April 22, 1:33 pm Eastern Time Company Press Release Sparta Pharmaceuticals Inc. Signs Drug Delivery Pact with Schering-Plough Corp. Spartaject(TM) Technology to be applied to TEMODAL(R) HORSHAM, Pa.--(BUSINESS WIRE)--April 22, 1998-- Sparta Pharmaceuticals Inc. (NASDAQ: SPTA, SPTAU, SPTAW, SPTAZ AND SPTAL) signed a license agreement with Schering-Plough Corp. (NYSE: SGP - news) for the use of Sparta's Spartaject(TM) technology. Spartaject will be applied to Schering-Plough's oral anticancer agent, TEMODAL(R) (temozolomide), which is currently in development for the treatment of patients with recurrent malignant gliomas, such as gliobastoma multiforme and anaplastic astrocytoma. Sparta's Spartaject technology is a drug delivery system that allows poorly water soluble and water insoluble compounds to be given by injection. The Spartaject technology encapsulates fine particles of a specified insoluble drug with a fatty (phospholipid) layer, permitting the creation of a suspension of the drug, and allowing its intravenous injection without the use of potentially toxic solubilizing agents. Sparta originally licensed the technology from RTP Pharma (Montreal). An advantage of the Spartaject technology is that it has the potential to be incorporated for use with many other drugs that are already FDA approved, yet only available by oral delivery. Currently, Phase I trials are underway in the US and UK using Spartaject(TM) busulfan, a product developed by Sparta. TEMODAL is an oral cytotoxic chemotherapeutic agent with demonstrated antitumor activity. Schering-Plough has exclusive worldwide rights to market temozolomide through a licensing agreement with Cancer Research Campaign Technology Ltd., of the United Kingdom. Sparta believes application of Spartaject to TEMODAL may allow for intravenous administration in patients that require high concentration levels in the blood and/or for the administration of TEMODAL in localized areas in direct contact with certain tumors. Dr. Jerry B. Hook, Sparta's chairman, president and CEO commented, ''We are pleased to be working with Schering-Plough in this effort to expand the TEMODAL product line. Spartaject Technology has proven to be an effective and potentially less toxic delivery system for water insoluble compounds. Our preliminary work with temozolomide has encouraged both companies to move forward with this project.'' Sparta will receive up-front licensing fees, milestone payments and royalties on sales. QED Technologies of Malvern, Pa. acted as an advisor to Sparta in this transaction. This press release contains certain forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs, and actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, including the success and timing of clinical trials and the receipt of necessary approvals by the FDA. The company undertakes no obligation to release publicly any revisions which may be made to reflect events or circumstances after the date hereof. Sparta is a development stage pharmaceutical company engaged in the business of acquiring rights to, and developing for commercialization, technologies and drugs for the treatment of a number of life threatening diseases including cancer, cardiovascular disorders, chronic metabolic diseases and inflammation. The company has focused on acquiring compounds that have been previously tested in humans and animals and technologies that may improve the delivery or effectiveness of previously tested, and in some cases marketed, drugs. Sparta's portfolio of compounds in development includes four potential oncology products and one for the treatment of Type II diabetes in clinical trials and an emerging platform technology in recombinant and small molecule protease inhibitors. -------------------------------------------------------------------------------- Contact: Sparta Pharmaceuticals Inc. Jerry B. Hook, Ph.D. Chairman, President & CEO 215/442-1700, Ext. 205 or Martin Rose, M.D.,J.D. Vice President, Clinical & Regulatory Affairs 215/442-1700, Ext. 219 >>>> --------------------------------------------------------------------------------